Article Text
PDF
Abstract
Introduction Stroke is a leading cause of mortality and morbidity worldwide. ICAS accounts for 10- 15% of ischemic stroke in Western countries.
Aim of Study To demonstrate the effectiveness of intracranial stenting in improving primary and secondary outcome and reducing recurrent stroke in ICAS.
Methods We included all intracranial stenting procedures performed in patients with symptomatic ICAS between 2022 and 2023.
We analyzed periprocedural complications, 30-days clinical improvement and death rates, 1 year rates of clinical improvment, stent patency and recurrent stroke.
Follow-up at 6 and 12 months was performed by DSA and neurological examination.
Results We enrolled 29 patients with TIA or symptomatic ischemic stroke related to ICAS, with a mean age of 65.7 years.
Two procedures required the deployment of 2 stents for a total of 31 stents.
Of the 29 patients, 18 were treated acutely (62.1%), 11 electively (37.9%).
We deployed 10 (32.3%) balloon-expandable stents and 21 (67.7%) self-expandable stents.
We encountered two periprocedural complications: a mild reperfusion hemorrhage and a stent occlusion 48 hours after the procedure, which was resolved deploying an additional stent; both cases had no neurological sequelae.
The mortality and clinical improvement rates at 30 days were 6.9% and 51%, respectively.
One-year follow-up documented 62% rate of clinical improvement, 100% stent patency and 2 new ischemic events.
One patient died during follow-up from unrelated causes
Conclusion Intracranial Stenting for ICAS is a safe and effective procedure to improve patient’s clinical outcome in the acute phase and reduce recurrent stroke.
Disclosure of Interest no.